Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results;Eficacia del sildenafilo por vía oral como terapia de rescate en pacientes con hipertensión arterial pulmonar severa en tratamiento crónico con prostaciclina. Resultados a largo plazo

Revista Espanola de Cardiologia

Volumn 57, Issue 10, 2004, Pages 946-951

  Jiménez López Guarch, Carmen ^a   Escribano Subias, Pilar ^a   de Meneses, Rocío Tello ^a   Delgado Jiménez, Juan F ^a   Sadia Pérez, David ^a   Velázquez Martín, M Teresa ^a   Gómez Sánchez, Miguel A ^a   de la Calzada, Carlos Sáenz ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Prostacyclin; Pulmonary hypertension; Sildenafil; Therapy

Indexed keywords

ILOPROST; PROSTACYCLIN; SILDENAFIL; UNIPROST;

ADULT; ARTICLE; CARDIOVASCULAR PARAMETERS; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL OBSERVATION; CONTROLLED STUDY; DETERIORATION; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART LEFT VENTRICLE; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE SIZE; HUMAN; IDIOPATHIC DISEASE; LONG TERM CARE; LUNG FUNCTION; MALE; PULMONARY HYPERTENSION; SATISFACTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUDDEN DEATH; TIME; TREATMENT OUTCOME; WALKING;

EID: 8344241223     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13066455     Document Type: Article

References (25)

1. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107:216-23.
2. Barst RJ, Rubin LJ, Long WA, McGoon M, Rich S, Badesh D, et al. A comparison of continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
3. Mc Laughlin V, Shillington A, Rich S. Survival in primary pulmonary hypertension. The impact of epoprostenol therapy. Circulation 2002;106:1477-82.
4. Pombo Jiménez M, Escribano Subias P, Tello de Meneses R, Gómez Sánchez MA, Delgado Jiménez JF, Dalmau González-Gallarza, et al. Experiencia de 10 años en el tratamiento con epoprostenol en perfusión intravenosa continua en hipertensión pulmonar arterial grave. Rev Esp Cardiol 2003; 56:230-5.
5. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin L, et al. Inhaled iloprost is an effective treatment for severe pulmonary hypertension: a double blind, placebo-controlled multicenter study. N Engl J Med 2002;342:1866-70.
6. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Boruge RC, et al. Continuous subcutaneous infusion of teprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double blind, randomized, placebo controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
7. Schalcher C, Schad K, Brunner-LaRoca H, Schindler R, Oeschlin E, Scharf C, et al. Interaction of sildenafil with cAMP-mediated vasodilatation in vivo. Hypertension 2002;40:763-7.
8. Stiebellehner L, Petkov V, Vonbank K, Funk G, Sxhenk P, Ziesche R, et al. Long-term treatment with oral sildenafil in addition to continuous iv epoprostenol in patients with pulmonary arterial hypertension. Chest 2003;123:1293-5.
9. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly R, Weissmann N, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-22.
10. Ghofrani HA, Rose F, Schermuly R, Olschewski H, Wiedemann R, Kreckel A, et al. Oral sildenafil as long term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158-64.
11. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, et al. Long term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-9.
12. Bhatia S, Frantz R, Severson C, Durst L, Mc Goon M. Immediate and long term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilatadory therapy. Mayo Clin Proc 2003;78:1207-13.
13. Rich S ed. Executive summary from de World Symposium on Primary Pulmonary hypertension 1998. Evian, France. September 6 to 10, 1998. World Health Organization.
14. Crapo R, Casaburi R, Coates A, Enright P, MacIntyre N, McKay R, et al, for the ATS board of directors. ATS statement: Guidelines for the six minutes walk test. Am J Respir Crit Care Med 2002;166:111-7.
15. Ryan T, Petrovic O, Dillon JC, Feigenbaum H, Conley MJ, Armstron WF. An echocardiographic index for separation of right ventricular volume and pressure overload. J Am Coll Cardiol 1985;5:918-24.
16. Tei C, Dujardin KS, Hodge DO, McGoon M, Tajick AJ, Seward J. Doppler echocardiographic index for assessment of global ventricular function. J Am Coll Cardiol 1996;26:838-47.
17. Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985;6:359-65.
18. Gómez Sánchez MA, Sáenz de la Calzada C, Gó mez Pajuelo C, Martínez Tello FJ, Mestre de Juan MJ, James TN. Clinical and pathologic manifestation of pulmonary vascular disease in the toxic oil syndrome. J Am Coll Cardiol 1991;18:1539-45.
19. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long term intravenous infusion of epoprostenol in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8.
20. Raymond RJ, Hinderliter AL, Wills PW, Ralph D, Caldwell EJ, Williams W, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214-9.
21. Galie N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:1380-6.
22. Hinderlitter AL, Willis PW, Barst RJ, Rich S, Rubin LJ, Badesch DB, et al. Effects of long term infusion of prostacyclin on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997;95:1479-86.
23. Rich S, Brundage BH. High dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence of long term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135-41.
24. Sebbag I, Rudski LG, Therrien J, Hirsch A, Langleben D. Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension. Am J Cardiol 2001;88:1060-3.
25. Mendeloff E, Meyers BF, Sundt T, Guthrie TJ, Sweet SC, Shapiro S, et al. Lung transplantation for pulmonary vascular disease. Ann Torac Surg 2002;73:209-17.